Downregulated CD44 and hyaluronan expression in vulvar intraepithelial neoplasia and squamous cell carcinomas

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 1, 2010, Pages 108-119

  Hämäläinen, Kirsi ^a,b   Kosma, Veli Matti ^a,b   Eloranta, Marja Liisa ^a   Tammi, Raija ^b   Tammi, Markku ^b   Leppänen, Marjo ^b   Leppänen, Merja ^b   Heinonen, Seppo ^a   Anttila, Maarit ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CD44; Hyaluronan; LS; VIN; Vulvar squamous cell carcinoma

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CELL MEMBRANE; DOWN REGULATION; FEMALE; HUMAN; LICHEN SCLEROSUS ET ATROPHICUS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; VULVA TUMOR;

ADULT; AGED; ANTIGENS, CD44; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; DOWN-REGULATION; FEMALE; HUMANS; HYALURONIC ACID; LICHEN SCLEROSUS ET ATROPHICUS; MIDDLE AGED; RETROSPECTIVE STUDIES; VULVAR NEOPLASMS;

EID: 74049112793     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903341990     Document Type: Article

References (42)

1. van de Nieuwenhof HP, van der Avoort IAM, de Hullu JA. Review of squamous premalignant vulvar lesions. Oncol Hematol. 2008; 68:131-56.
2. Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathol. 2003; 42:209-16.
3. Tammi MI, Day AJ, Turley EA Hyaluronan and homeo-stasis: a balancing act. J Biol Chem. 2002; 277:4581-4.
4. Laurent TC, Laurent UB, Fraser JR Functions of hyaluro-nan. Ann Rheum Dis. 1995; 54:429-32.
5. Menzel EJ, Farr C. Hyaluronidase and its substrate hyalur-onan: biochemistry, biological activities and therapeutic uses. Cancer Let. 1998; 131:3-11.
6. Rooney P, Kumar S, Ponting J., Wang M. The role of hyalur-onan in tumour neovascularisation (review). Int J Cancer. 1995; 60:632-6.
7. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiol. 2002; 12:37-42.
8. Lipponen P, Aaltomaa S, Tammi R., Tammi M, Ågren U, Kosma VM. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer. 2001; 37:849-56.
9. Anttila MA, Tammi RH, Tammi M.I., Syrjänen KJ, Saarikoski S.V., Kosma VM High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 2000; 60:150-5.
10. Auvinen P, Tammi R, Parkkinen J., Tammi M, Ågren U, Johansson R, et al. Hyaluronan in peritumoural stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol. 2000; 156:529-36.
11. Ropponen K, Tammi M, Parkkinen J., Eskelinen M, Tammi R, Lipponen P., et al Tumour cell-associated hyalur-onan as an unfavourable prognostic factor in colorectal cancer. Cancer Res. 1998; 58:342-7.
12. Setälä LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK, Ågren UM, et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer. 1999; 79:1133-8.
13. Kosunen A, Ropponen K, Kellokoski J., Pukkila M, Virtaniemi J, Valtonen H., et al Reduced expression of hya-luronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol. 2004; 40:257-63.
14. Hirvikoski P, Tammi R, Kumpulainen E., Virtaniemi J, Parkkinen J, Tammi M., et al Irregular expression of hyalur-onan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch. 1999; 434:37-44.
15. Knudson W, Chow G, Knudson CB. CD-44-mediated uptake and degradation of hyaluronan. Matrix Biol. 2002; 21: 15-23.
16. Joensuu H, Ristamäki R, Klemi P.J., Jalkanen S. Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer. 1993; 68:428-32.
17. Kauffmann M, Heider KH, Sinn H.P., von Minkwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and legth of survival. Lancet. 1995; 345: 615-19.
18. Kainz CH, Kohleberger P, Sliutz G., Tempfer C, Heinzl H, Reinthaller A., et al Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol. 1995; 57:383-7.
19. Underhill C. CD44: the hyaluronan receptor. J Cell Sci. 1992; 103:293-8.
20. Ropponen KM, Eskelinen MJ, Lipponen P.K., Alhava E., Kosma VM Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol. 1998; 33:301-9.
21. Tempfer C, Gitsch G, Haeusler G., Reinthaller A, Koelbl H, Kainz C. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Cancer. 1996; 15:273-7.
22. Hefler LA, Concin N, Mincham D., Thompson J, Swarte NB, van Ejkeren MA, et al The prognostic value of immunohis-tochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma. Cancer. 2002; 94:125-30.
23. Tempfer C, Gitsch G, Hanzal E., Reinthaller A, Koelbl H, Kainz CH Expression of the adhesion molecule CD44v3 is a prognostic factor in vulvar carcinoma. Anticancer Res. 1996; 16:2029-31.
24. Tempfer C, Sliutz G, Hausler P., Speiser P, Reinthaller A, Breitenecker G., et al C44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer. Br J Cancer. 1998; 78:1091-4.
25. Rodriguez-Rodriguez L., Sancho-Torres I, Gibbon D.G., Watelet LF, Mesonero C. CD44-9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva. J Soc Gynecol Investig. 2000; 7:70-5.
26. Sobin LH, Wittekind CH In: TNM classification of malignant tumours, 6th edn. Geneva Switzerland: UICC, 2002. pp. 146-9.
27. Tavassoli FA, Devilee P. In WHO Health Organization Classification of tumours. Pathology & Genetics. Tumours of the breast and female genital organs. Lyon, France: IARC Press; 2003. pp. 314-20.
28. Wang C, Tammi M, Tammi R. Distribution of hyaluronan and its CD44 receptor in the epithelia of human skin appendages. Histochemistry. 1992; 98:105-12.
29. Ingle RK, Jennings TA, Goodman M.L., Pilch BZ, Bergman S, Ross JS CD44 expression in sinonasal inverted papillomas and associated squamous cell carcinoma. Am J Clin Pathol. 1998; 109:309-14.
30. Wang C, Tammi M, Guo H., Tammi R. Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol. 1996; 148:1861-9.
31. Karvinen S, Kosma VM, Tammi M.I., Tammi R. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol. 2003; 148:86-94.
32. Kunishi M, Kayada Y, Yoshiga K. Down-regulated expression of CD44 variant 6 in oral squamous cell carcinomas and its relationship to metastasis. Int J Oral Maxillofac Surg. 1997; 26:280-3.
33. Ue T, Yokozaki H, Kagai, Higashikawa K, Yasui W, Sugiyama M, et al. Reduced expression of CD44 variant exons by primary and metastatic oral squamous carcinomas. J Oral Pathol Med. 1998; 27:303-7.
34. Oliveira DT, Sherrif M, Odell EW Expression of CD44 variant exons by primary and metastatic oral squamous carcinomas. J Oral Pathol Med. 1998; 27:303-7.
35. Stoll C, Baretton G, Soost, Terpe HJ, Domide P, Lohrs U. Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol. 1999; 35:484-9.
36. Saegusa M, Hashimura M, Machida D., Okayasu I. Down-regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours. J Pathol. 1999; 187:173-83.
37. Callagy G, O'Grady A, Butler D, Leader M., Kay E. Expression of CD44 in uterine cervical squamous neoplasia: A predictor of microinvasion? Gyn Oncol. 2000; 76:73-9.
38. Tammi R, Rilla K, Pienimäki J-P, MacKallum D, Hogg M, Luukkonen M, et al. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem. 2001; 37:35111-22.
39. Pirinen RT, Tammi RH, Tammi M.I., Pääkkö PK, Parkkinen JJ, Ågren UM, et al. Expression of hyaluronan in normal and dysplastic bronchial epithelium and in squamous cell carcinoma of the lung. Int J Cancer. 1998; 79:251-5.
40. Kaya G, Rodriguez I, Jorcano J., Vassali P, Stamenkovic I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-spesific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 1997; 11:996-1007.
41. Kuroda K, Fujimoto N, Tajima S. Abnormal accumulation of inter-alfa-trypsin inhibitor and hyaluronic acid in lichen scler-osus. J Cutan Pathol. 2005; 32:137-40.
42. Farrell AM, Marren P, Dean D., Wojnarowska F. Lichen sclerosus: evidence that immunological changes occur at all levels of the skin. Br J Dermatol. 1999; 140:1087-92.